We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
JULUCA (ViiV Healthcare Pty Ltd)
Product name
JULUCA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
169 working days (255)
Active ingredients
rilpivirine hydrochloride; dolutegravir
Registration type
EOI
Indication
New combination
JULUCA (tablets) is now also indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.